ロード中...
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
BACKGROUND: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety profile of exenatide twice daily and to compare its profile with that of a pooled comparator (placebo...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3287409/ https://ncbi.nlm.nih.gov/pubmed/22375098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S28387 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|